SaveRxCanada.to Offers Significant Cost Savings on Lung Cancer Drug Tagrisso from India

An online pharmacy is offering U.S. patients substantial cost savings on Tagrisso, a targeted lung cancer therapy, by sourcing the medication from licensed Indian suppliers. SaveRxCanada.to reports that patients could reduce monthly medication expenses from $15,000-$18,000 to approximately $12,500, representing potential annual savings of over $66,000.

Tagrisso, developed by AstraZeneca, is a critical treatment for non-small cell lung cancer (NSCLC) patients with specific EGFR mutations. The medication targets both common genetic variations and the resistant T790M mutation, offering improved survival outcomes for patients who have progressed through earlier treatments.

The drug is designed for first-line NSCLC treatment and serves patients whose cancer has advanced despite previous targeted therapies. While generally well-tolerated, patients may experience side effects including diarrhea, rash, skin changes, fatigue, and decreased appetite.

This cost-reduction strategy could significantly impact patient access to expensive cancer treatments, potentially allowing more individuals to afford critical medication. By partnering with international licensed suppliers, SaveRxCanada.to aims to provide authentic medications at substantially reduced prices without compromising quality or efficacy.